Pharmacokinetic Characteristics of Drugs and Their Effects on Therapeutic Efficacy and Safety
Received: 2026-02-10Accepted: 2026-03-15Published: 2026-06-10
Int. J. Pharm. & Pharmacol. 2026, 17(1), 7-13; https://doi.org/10.58244/ijpp.263903
Abstract
The absorption, distribution, metabolism, and excretion of drugs in the body collectively shape the exposure-time curve, which largely determines the intensity of therapeutic response, onset rate, duration, and spectrum of adverse reactions. With the advancement of new drug development and the concept of personalized treatment, the issue of significant differences in exposure at the same dose regimen, as well as inconsistent efficacy and toxicity profiles, has become increasingly prominent. Pharmacokinetic (PK) characteristics thus serve as the critical link connecting "dose-exposure-therapeutic effect/safety." This article systematically reviews the core concepts of PK from four dimensions—absorption, distribution, metabolism, and excretion—explains their impact pathways on onset and duration, targeting and therapeutic window, as well as acute and chronic toxicity risks. Based on this, it discusses clinical optimization strategies for drug use based on pharmacokinetic characteristics, providing insights for exposure control, risk identification, and individualized dosing.
Keywords: Drug exposure; Therapeutic window; Individualized dosing
Full Text
Download the full text PDF for viewing and using it according to the license of this paper.
Funding
This research was no funding provided.
References
- Kruse M, Stankeviciute S, Perry S. Clinical pharmacology—how it shapes the drug development journey[J]. European Journal of Clinical Pharmacology, 2025: 1-8.
- Widmer N, Guidi M, Buclin T. Population Pharmacokinetics in Oncology and Its Clinical Applications[J]. Pharmaceutics, 2024, 16(6): 711.
- Habet S.[3]Habet S. Narrow therapeutic index drugs: clinical pharmacology perspective[J]. Journal of Pharmacy and Pharmacology, 2021, 73(10): 1285-1291.
- Lee J L, Shah N M, Makmor-Bakry M, [4]Lee J L, Shah N M, Makmor-Bakry M, et al. A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy[J]. International Immunopharmacology, 2021, 97: 107721.
- Lennernäs H, Cook J, Hesselink D A. Therapeutic drug monitoring—Does it really matter?[J]. British Journal of Clinical Pharmacology, 2025, 91(6): 1527-1529.
